Appendix B: Acronyms
Updated
Reviewed
| Acronym | Term |
|---|---|
| °C | degrees Celsius |
| °F | degrees Fahrenheit |
| % v | volume |
| 25-OH-vitamin D | 25-hydroxy vitamin D |
| AAP | American Academy of Pediatrics |
| ACTH | adrenocorticotropic hormone |
| AE | adverse effect or adverse event |
| AHR | adjusted hazard ratio |
| ALT | alanine aminotransferase |
| ANC | absolute neutrophil count |
| app | mobile application |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| ATI | analytical treatment interruption |
| AUC | area under the curve |
| AUC0-12h | area under the curve from time zero to 12 hours postdose |
| AUC12h | 12-hour area under the curve |
| AUC0–24h | area under the curve from time zero to 24 hours postdose |
| AUC24h or | 24-hour area under the curve |
| AUCinf | area under the concentration time curve extrapolated to infinity |
| AUCtau | area under the concentration time curve over the dosing interval |
| AV | atrioventricular |
| BCRP | breast cancer resistance protein |
| BHIVA | British HIV Association |
| BMD | bone mineral density |
| BMI | body mass index |
| BSA | body surface area |
| C0h | pre-dose concentration |
| C12h | concentration at 12 hours |
| C24h | concentration at 24 hours |
| Cavg | average plasma concentration |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| Ctau | concentration at the end of a dosing interval |
| Ctrough | trough concentration |
| CAR | chimeric antigen receptor |
| cART | combination antiretroviral therapy |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CD8 | CD8 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CEPAC | Cost-Effectiveness of Preventing AIDS Complications, a model |
| CI | confidence interval |
| CK | creatine kinase |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| COMB-R | cognitive behavioral therapy and medication management algorithm |
| Cr | creatinine |
| CRAFFT | Car, Relax, Alone, Forget, Friends, and Trouble (questionnaire) |
| CrCl | creatinine clearance |
| CT | continuous therapy |
| CV | cardiovascular or coefficients of variation |
| CVD | cardiovascular disease |
| CYP | cytochrome P450 |
| CYPB26 | cytochrome P450 family 2 subfamily B member 6 |
| CYP3A | cytochrome P450 3A substrate |
| DAIDS | Division of AIDS (National Institute of Allergy and Infectious Diseases) |
| DBS | dried blood spot |
| DM | diabetes mellitus |
| DOT | directly observed therapy |
| DRESS | drug reaction (or rash) with eosinophilia and systemic symptoms |
| DT | dispersible tablet |
| DXA | dual energy X-ray absorptiometry |
| EBV | Epstein-Barr virus |
| EC | enteric-coated |
| EC50 | half maximal effective concentration |
| EC90 | 90% effective concentration |
| ECG | electrocardiogram |
| ECMO | extra corporeal membrane oxygenation |
| EEG | electroencephalogram |
| eGFR | estimated glomerular filtration rate |
| EM | erythema multiforme or extensive metabolizer |
| FCT | film-coated tablet |
| FDA | U.S. Food and Drug Administration |
| FDC | fixed-dose combination |
| FLP | fasting lipid profile |
| FPG | fasting plasma glucose |
| GA | gestational age |
| GI | gastrointestinal |
| GLSM | geometric least squares mean |
| GM | geometric mean |
| GMR | geometric mean ratio |
| gp120 | glycoprotein 120 |
| HA | height age |
| HAV | hepatitis A virus |
| HBcAB | hepatitis B virus core antibody |
| HBsAB | hepatitis B virus surface antibody |
| HBsAG | hepatitis B virus surface antigen |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HD | high dose |
| HDL | high-density lipoprotein |
| HDL-C | high-density lipoprotein cholesterol |
| Hgb | hemoglobin |
| HgbA1c | glycosylated hemoglobin |
| HHS | U.S. Department of Health and Human Services |
| HIV RNA or HIV-1 RNA | viral load |
| HLA | human leukocyte antigen |
| HMG-CoA | 3-hydroxy-3-methylglutaryl coenzyme A |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| HSV | herpes simplex virus |
| IC90 | 90% maximal inhibitory concentration |
| IFPG | impaired fasting plasma glucose |
| IGRA | interferon gamma release assay |
| IGT | impaired glucose tolerance |
| IM | intramuscular |
| IMT | intima-media thickness |
| INSTI | integrase strand transfer inhibitor |
| IQ | inhibitory quotient |
| IQR | interquartile range |
| IR | insulin resistance |
| IRIS | immune reconstitution inflammatory syndrome |
| IU | international unit |
| IV | intravenous |
| IVIG | intravenous immune globulin |
| LA | long-acting |
| LAI | long-acting injectable |
| LBW | low birth weight |
| LDL | low-density lipoprotein |
| LDL-C | low-density lipoprotein cholesterol |
| LFT | liver function test |
| Log10 | the logarithm to the base 10 |
| LS | lipodystrophy syndrome or lumbar spine |
| LVH | left ventricular hypertrophy |
| MCV | mean cell volume |
| MEMS | medication event monitoring system |
| N/A | not available or not applicable |
| NASBA | nucleic acid sequence-based amplification |
| NAT | nucleic acid test |
| NHLBI | National Heart, Lung, and Blood Institute |
| NHSS | National HIV Surveillance System |
| NIH | National Institutes of Health |
| nM | nanometer |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NPHIV | non-perinatally transmitted HIV |
| NRTI | nucleoside reverse transcriptase inhibitor |
| OARAC | Office of AIDS Research Advisory Council |
| OAT | organic anion transporter |
| OATP | organic anion transporter polypeptide |
| OATP1B1 | organic anion transporter polypeptide 1B1 |
| OBT | optimized background therapy |
| OGTT | oral glucose tolerance test |
| OI | opportunistic infection |
| OR | odds ratio |
| P-gp | P-glycoprotein |
| PA-IC95 | protein-adjusted IC95 |
| The Panel | the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV |
| PBMC | peripheral blood mononuclear cell |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PEPFAR | President's Emergency Plan for AIDS relief |
| PG | plasma glucose |
| PHIV | perinatally acquired HIV |
| PI | protease inhibitor |
| PK | pharmacokinetic |
| POC | point of care |
| popPK | population PK |
| PPI | proton pump inhibitor |
| PR | P wave to onset of atrial depolarization |
| PrEP | pre-exposure prophylaxis |
| PWV | pulse wave velocity |
| QTc | QT corrected for heart rate |
| RCT | randomized controlled trial |
| RPG | random plasma glucose |
| RR | relative risk |
| RT-PCR | reverse transcription polymerase chain reaction |
| SAM | severe acute malnutrition |
| SBIRT | Screening, Brief Intervention, and Referral to Treatment |
| SCT | short-cycle therapy |
| SD | standard deviation |
| SJS | Stevens-Johnson syndrome |
| SM | slow metabolizer |
| SMR | sexual maturity rating |
| SMS | short message service |
| SOC | standard of care |
| SQ | subcutaneous |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| T½ | half-life |
| TB | tuberculosis |
| TBLH | total body less head |
| TC | total cholesterol |
| TDM | therapeutic drug monitoring |
| TEN | toxic epidermal necrolysis |
| TG | triglyceride |
| TIC | trauma-informed care |
| TMA | transcription-mediated amplification |
| Tmax | time to reach maximum concentration |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1A | uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex |
| UGT1A1 | uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex 1 |
| ULN | upper limit of normal |
| v/v | volume per volume |
| w | weight |
| w/v | weight per volume |
| WHO | World Health Organization |
| XR | extended release |
Download Guidelines
- Section Only PDF (80.89 KB)
- Full Guideline PDF (6.37 MB)
- Recommendations Only PDF (247.86 KB)
- Tables Only PDF (1.05 MB)
- Drug Tables Only PDF (2.4 MB)